Disturbances in B- and T-cell homeostasis in rheumatoid arthritis: Suggested relationships with antigen-driven immune responses

Fekete, Andrea; Soós, Lilla; Szekanecz, Zoltán; Szabó, Zoltán; Szodoray, Péter; Baráth, Sándor; Lakos, Gabriella

doi:10.1016/j.jaut.2007.07.002

Cited by 52 publications

(40 citation statements)

References 49 publications

(63 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…+ memory B cells are reported in RA patients with long-standing disease [29]. The disparities between our data and the results of previous studies may be due to a number of factors, including varying genetic backgrounds, disease duration, cohort size and therapy.…”

Section: Cd27contrasting

confidence: 97%

High frequencies of activated B cells and T follicular helper cells are correlated with disease activity in patients with new-onset rheumatoid arthritis

Wang

Shan

Jiang

et al. 2013

Clinical and Experimental Immunology

171

166

View full text Add to dashboard Cite

show abstract

Section: Cd27contrasting

confidence: 97%

High frequencies of activated B cells and T follicular helper cells are correlated with disease activity in patients with new-onset rheumatoid arthritis

Wang

Shan

Jiang

et al. 2013

Clinical and Experimental Immunology

171

166

View full text Add to dashboard Cite

show abstract

“…The contribution of preswitch memory B cells in RA seems to be the most controversial feature. The levels have been reported to be comparable to those in healthy controls (29), but other investigators found a lower frequency of these cells in the periphery (31), particularly in patients with very early RA and a disease duration of less than 6 months (32). Also, anti-TNF␣ therapy seems to be related to increased numbers of preswitch memory B cells (31,33).…”

Section: Discussionmentioning

confidence: 75%

“…These results have some limitations, since they may reflect the specific composition of our patient cohort with regard to disease duration, anti-CCP status, or prior treatment with anti-TNF agents, all of which have been indicated to influence B cell homeostasis. Nevertheless, other studies have also reported a significant increase in overall peripheral memory B cells in RA patients (28), particularly the postswitch memory B cell subset (29). The contribution of preswitch memory B cells in RA seems to be the most controversial feature.…”

Section: Discussionmentioning

confidence: 97%

“…In mouse models, IL-6 is reported to be involved in B cell hyperactivity, autoantibody production, and immunopathology (27). In RA patients, chronic activation of B cells and an accumulation of memory B cells in the peripheral blood and the synovial membrane have been described (28,29). Within this context, B cell-targeted therapies have been widely explored in RA (30).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

In vivo effects of the anti–interleukin‐6 receptor inhibitor tocilizumab on the B cell compartment

Roll¹,

Muhammad²,

M³

et al. 2011

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. Interleukin-6 (IL-6) receptor inhibition by tocilizumab was recently licensed for the treatment of rheumatoid arthritis (RA). IL-6 induces in vitro differentiation of B cells into antibody-forming cells; however, the in vivo effects of IL-6 inhibition on the B cell compartment are currently not known. The purpose of this study was to examine this feature.Methods. Sixteen patients with active RA were treated in an open-label study with tocilizumab (8 mg/kg every 4 weeks). Immunophenotyping was performed at baseline, week 12, and week 24.Results. Memory B cell subsets declined significantly during tocilizumab therapy. Preswitch memory B cells decreased from a median of 19.6% to 12.3% at week 24 and postswitch memory B cells declined from a median of 18.6% to 15.0% at week 24 (P ‫؍‬ 0.04). In parallel, CD19؉IgA؉ and CD19؉IgG؉ B cells decreased significantly. The proportion of IgA-expressing B cells fell from a median of 9.2% at baseline to 4.3% at week 12 and to 3.6% at week 24 (P ‫؍‬ 0.01). IgG؉ B cells declined from a median of 6.7% at baseline to 4.9% at week 12 (P ‫؍‬ 0.007) and 2.8% at week 24 (P ‫؍‬ 0.01). In parallel, serum levels of IgA and IgG were significantly diminished at week 24 (P < 0.05). There was a good correlation between relative and absolute numbers of IgA؉ B cells with serum IgA at week 24.Conclusion. Tocilizumab induced a significant reduction in the frequency of peripheral preswitch and postswitch memory B cells. In addition, the number of IgG؉ and IgA؉ B cells declined and correlated well with reduced serum immunoglobulin levels. The data indicate that IL-6 blockade affects the B cell hyperreactivity in RA patients.

show abstract

“…An abnormal variation in the number of peripheral blood memory B cells has been reported in systemic lupus erythematosus (Odendahl et al, 2003), Sjögren's syndrome (Hansen et al, 2002), and RA (Souto-Carneiro et al, 2009). Antigen-specific memory B cells, residing either in secondary lymphoid organs or the bone marrow, persist for decades (Yu et al, 2008), and are responsible for the chronic nature of autoimmune disease (Fekete et al, 2007). In fact, compared with naïve B cells, memory B cells easily differentiate into plasma cells (DiLillo et al, 2008;Huard et al, 2008).…”

Section: Discussionmentioning

confidence: 99%

The ginsenoside metabolite compound K exerts its anti-inflammatory activity by downregulating memory B cell in adjuvant-induced arthritis

Chen

Wang

et al. 2016

Pharmaceutical Biology

View full text Add to dashboard Cite

(2016) The ginsenoside metabolite compound K exerts its anti-inflammatory activity by downregulating memory B cell in adjuvant-induced arthritis, Pharmaceutical Biology, 54:7, 1280-1288, DOI: 10.3109/13880209.2015 PHARMACEUTICAL BIOLOGY, 2016 VOL. 54, NO. 7, 1280-1288 http://dx.doi.org/10.3109/13880209.2015 ORIGINAL ARTICLEThe ginsenoside metabolite compound K exerts its anti-inflammatory activity by downregulating memory B cell in adjuvant-induced arthritis + (memory B cells) and expression of CD40 and CD40L were assayed by flow cytometry. Results: Compared with the AA rats, global assessment scores and swollen joint counts were significantly lower in the treated groups received CK (40 and 160 mg/kg; p50.05 and p50.01, respectively). CK (40 and 160 mg/kg) decreased the spleen index (p50.01), and alleviated hyperplasia of lymph nodes (p50.05 and p50.01, respectively) and marginal zone (p50.05) in the spleen. In addition, CK (40 and 160 mg/kg) suppressed memory B cell subsets (p50.05), and suppressed CD40L expression on T cells and CD40 expression on B cells (p50.05 and p50

show abstract

Disturbances in B- and T-cell homeostasis in rheumatoid arthritis: Suggested relationships with antigen-driven immune responses

Cited by 52 publications

References 49 publications

High frequencies of activated B cells and T follicular helper cells are correlated with disease activity in patients with new-onset rheumatoid arthritis

High frequencies of activated B cells and T follicular helper cells are correlated with disease activity in patients with new-onset rheumatoid arthritis

In vivo effects of the anti–interleukin‐6 receptor inhibitor tocilizumab on the B cell compartment

The ginsenoside metabolite compound K exerts its anti-inflammatory activity by downregulating memory B cell in adjuvant-induced arthritis

Contact Info

Product

Resources

About